In this study, we used automated CLIA to show that the level of EphA2-NF, produced by the proteolytic cleavage of EphA2, was elevated in patient sera from early-stage pancreatic cancer and at pancreatic cancer development from IPMN. This evidence concerns the gene EPHA2 and pancreatic intraductal papillary-mucinous neoplasm.